摘要
目的 分析单药紫杉醇治疗晚期乳腺癌剂量强度与疗效和毒性的关系。方法 71例晚期乳腺癌患者 ,接受不同剂量强度的单药紫杉醇治疗。根据国际推荐方案 (每 3周 175mg/m2 ) ,标准剂量强度定义为每周 5 8.3mg/m2 。本组患者给药剂量范围每周 33.3～ 70 .3mg/m2 ,中位剂量强度为每周 5 8.8mg/m2 。评估紫杉醇剂量强度与疗效及毒性的关系。结果 全组患者的总有效率为4 0 .8% ,其中肺、软组织、骨及肝脏转移者 ,有效率分别为 5 2 .0 %、38.0 %、12 .5 %和 7.7%。相对剂量强度 >1.0、0 .9～ 1.0和 <0 .9时 ,全组患者的有效率分别为 4 4 .2 %、4 7.6 %和 0 ;相对剂量强度 0 .9～1.0和 <0 .9比较 ,差异有统计学意义 (P <0 .0 5 )。患者对毒副作用耐受良好 ,随着相对剂量强度降低 ,疗效降低 ,但毒性不减低。结论 单药紫杉醇治疗晚期乳腺癌患者时 ,按标准剂量强度应用是安全有效的。
Objective To evaluate the relation of dose intensity and efficacy, toxicity in advanced breast cancer treated with paclitaxel as a single agent. Methods Seventy one patients with advanced breast cancer received paclitaxel as a single agent with different dose intensities. According to the phase Ⅰor phaseⅡtrial, the standard dose intensity of paclitaxel was defined as 58.3 mg·(m 2) -1 ·week -1 . The dose of paclitaxel was 175 mg/m 2 given every three weeks, ranging 33.3 70.3 mg·(m 2) -1 ·week -1 [median delivered dose intensity 58.82 mg·(m 2) -1 ·week -1 ]. Efficacy and toxicity was evaluated. Results The overall response rate in this group of advanced breast cancer was 40.8%. Responses were seen in lungs, soft tissue, bone and liver,with the response rates of 52.0%、38.0%、12.5%、7.7%, respectively. When the relative dose intensity (RDI) was>1.0、0.9 1.0、<0.9, the response rates were 44.2%、47.6%、0, respectively. The difference between the group (RDI ≥0.9% 1.0%) in 7 patients and the group (RDI<0.9) was significant ( P <0.05). Toxicity was well tolerated, with the efficacy decreased as soon as the RDI had been reduced without embarassing the toxicity. Conclusion Paclitaxel as a single agent therapy with standard dose intensity is effective and well tolerated by patients with advanced breast cancer.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2005年第1期56-58,共3页
Chinese Journal of Oncology
